Johns Hopkins scientists depict molecular pathway to track replication in cancer cells
The findings could potentially lead to new therapies and could stop the growth of cancers
Read Moreby Jen Brogan | May 8, 2024 | News | 0
The findings could potentially lead to new therapies and could stop the growth of cancers
Read Moreby Jen Brogan | Apr 26, 2024 | News | 0
The paper identifies the roles and differences between LARP4A and LARP4B in sarcoma and carcinoma cancers
Read Moreby Jen Brogan | Apr 19, 2024 | News | 0
Both will develop cancer vaccine candidates in selected haematological and solid tumour indications
Read Moreby Jen Brogan | Apr 12, 2024 | News | 0
NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases
Read Moreby Jen Brogan | Apr 11, 2024 | News | 0
Prostate cancer is responsible for around 12,000 deaths a year in the UK and is the second biggest cause of death for men
Read Moreby Jen Brogan | Apr 10, 2024 | News | 0
Solid tumour cancers account for 90% of adult human cancers and 50% of childhood malignancies
Read Moreby Jen Brogan | Apr 9, 2024 | News | 0
Both will validate the clinical performance of two new diagnostic tests for regulatory submission
Read Moreby Jen Brogan | Apr 8, 2024 | News | 0
Macmillan Cancer Support estimated that around three million people in the UK were living with cancer in 2022
Read Moreby Jen Brogan | Apr 5, 2024 | News | 0
Hoxa9 and b-catenin molecules are a rare population of self-renewing HSCs found in bone marrow
Read Moreby Jen Brogan | Apr 4, 2024 | News | 0
The project will assist researchers and companies in training the technology for healthcare settings
Read Moreby Jen Brogan | Apr 3, 2024 | News | 0
The third most common and serious form of cancer affects over 43,000 people every year in the UK
Read Moreby Jen Brogan | Mar 28, 2024 | News | 0
The self-replicating mRNA molecule could be used in cancer and potentially a broad range of other diseases
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479